Psychopharmacol Bull 2022 02;52(1):57-60
Naguy, MBBch, MSc, Child/Adolescent Psychiatrist, Al-Manara CAP Centre, Kuwait Centre for Mental Health (KCMH), Jamal Abdul-Nassir St, Shuwaikh, State of Kuwait. Rushdy, MD, PhD, Professor of Psychiatry, Psychiatry Departments, Al-Azhar University, Cairo, Egypt. Pridmore, MD, Professor of Psychiatry, University of Tasmania, Hobart, Australia. Singh, MBBch, MD, Mrcpsych (UK), Speciality Doctor, Learning Disabilities, Exeter, Devon NHS partnership Trust, UK, and Assistant Professor, Psychiatry, Saraswati medical college, Lucknow, India. Alamiri, MD, ABPN, ScD, Consultant Psychiatrist, Chairperson, Al-Manara CAP Centre, KCMH, Kuwait, and Tufts University, Medford, United States.
Early-onset schizophrenia is notorious for poor prognostication and treatment-refractoriness. Clozapine remains a viable option, albeit off-label, but is clearly underutilized in this population. Use is typically fraught with panoply of drastic side effects. Read More